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credible interval: 1.4 to 14.8). Results of synthesizing IPD using information on a
covariate account for possible ecological bias and show a clear improvement in
accuracy over estimated treatment-covariate interactions, when compared to re-
sults obtained from synthesizing AD. CONCLUSIONS: Including evidence at IPD
level in the MTC is advisable when exploring participant level covariates; even
when IPD are only available for a fraction of the studies forming the evidence base.
Our findings suggest that adjusting for covariates impact produces intervention
effect estimates of higher accuracy, which is valuable for estimating subgroup
effects or adjusting for inconsistency.
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OBJECTIVES: International health technology assessment is increasingly inter-
ested in the rapid review of technologies. In the UK NICE Single Technology Ap-
praisal (STA) process, manufacturers present the clinical and cost effectiveness of
new technologies in their evidence submissions. These submissions are critically
appraised by Evidence Review Groups (ERGs) who produce a report which forms
part of the evidence considered by the Appraisal Committees. Early on in the pro-
cess the ERG requests more information from the manufacturer via a clarification
letter. The purpose of this research was to analyse ERG reports and clarification
letters in order to develop guidance for manufacturers based on common problems
or issues identified in manufacturer submissions (MS). METHODS: A thematic
analysis of the first 30 completed ERG reports was undertaken using a framework
approach. Twenty one of the available associated clarification letters were anal-
ysed using a set of open codes to analyse data. Both sources of evidence were used
to identify common issues and concerns. RESULTS: Inadequate reporting of pro-
cesses was identified in 90% of reports; criticisms of data used, especially in the
model was mentioned for 67% of the reports and issues with the conduct of the
systematic review in 57%. The population and comparator represented the key
items in the decision problem assessed by the ERGs as being inadequately ad-
dressed by manufacturers. The majority of clarification points related to the eco-
nomic data analysis. Issues identified included clarification of data sources and
selection, queries about modelling decisions and requests for additional analyses.
Internal inconsistencies between the clinical and economic sections of the MS and
inconsistencies within the economic section of the MS were also identified as
particular problems. This analysis was used as the basis for the development of 12
recommendations for manufacturers. CONCLUSIONS: These recommendations
may help to improve the quality of manufacturers’ submissions.
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OBJECTIVES: Health technology assessments (HTAs) have the potential to influ-
ence the diffusion of medical devices into health care systems. This study investi-
gates the impact the National Institute for Health and Clinical Excellence’s (NICE)
technology appraisals have on the diffusion of implantable devices in the UK (UK).
METHODS: The analysis focused on the impact of NICE guidance on volume sold of
three medical devices: drug eluting stents (DES), implantable cardioverter defibril-
lators (ICD), and spinal cord stimulators (SCS). UK sales data (2005-2010) for each
device were collected from Eucomed and other industry sources. Diffusion pat-
terns before and after publication of NICE guidance were analyzed from an aggre-
gated market-level perspective. A linear regression model was fit to the time series
data to illustrate the relationship between the NICE decision and volume.
RESULTS: The results from the statistical analysis show that NICE guidance has
different effects on diffusion across products. NICE guidance had a step increase
impact in adoption of DES and SCS (p0.026 and p0.00, respectively).The model
suggests that the NICE review did not predict the diffusion of ICDs. Descriptive
analysis demonstrated that for SCS and ICDS the NICE decision had a positive effect
and no impact on DES diffusion on volume over time. Overall the units sold were
positively and significantly correlated with time post-NICE guidance.
CONCLUSIONS: The study indicates that NICE guidance influences the adoption of
medical devices. Positive recommendations were associated with an increase in
units sold despite a decrease in units sold experienced before the final recommen-
dation. Additionally, the analysis suggests that there may be a lag between a pos-
itive NICE decision and adoption of guidance recommendations in practice. Lastly,
there were no consistent trends on NICE’s effect on the rate of diffusion. More
research is needed to clearly understand the dynamics of HTAs on technology
adoption.
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OBJECTIVES: The Advisory Group for National Specialised Services (AGNSS) is a
new committee that advises health ministers on which orphan services, including
orphan drugs, should be nationally commissioned. The aim of this paper is to
provide a description of AGNSS priorities, budget, and synergies with the National
Institute for Health and Clinical Excellence (NICE), and an analysis of the decision-
making framework used by AGNSS to recommend new drugs and technologies.
METHODS:A web-based search was conducted for articles and information related
to the specialized services of the National Health Service (NHS) and NICE. All doc-
uments, including AGNSS meeting minutes were analyzed to provide a compre-
hensive understanding of the AGNSS program. RESULTS: Beginning in 2010 and
each year thereafter, AGNSS will recommend approximately 60 highly specialized
services and a small number of new drugs and technologies that affect fewer than
500 patients in England. Drugs and stand-alone technologies first must be submit-
ted to NICE. Based on prevalence, disease severity, resource impact, and clinical
benefit, a subset of these are referred to AGNSS for consideration. AGNSS can
recommend “accept” or “accept with conditions” when the application meets the
quality, innovation, productivity, and prevention criteria, or will recommend to
“defer” or “reject” otherwise. Currently, AGNSS has identified eight priority areas
for 2011-2012. The total program budget in 2010/11, excluding three high-cost drugs
categories, is expected to be about £348 millions. Additionally, the planned budget
for high-cost drugs such as enzyme replacement therapy, paroxysymal nocturnal
hemoglobinuria (PNH), and cryopyrin-associated periodic syndromes (CAPS) is
£128,879, £27,592, and £3,080 million, respectively. CONCLUSIONS: Under the cur-
rent NHS framework, access to orphan drugs can be denied if they surpass NICE
implicit willingness to pay thresholds. The introduction of AGNSS offers an alter-
native evaluation mechanism, one that potentially offers the flexibility necessary
to comprehensively review orphan drugs and services.
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OBJECTIVES: To estimate the relationship between the maximum possible finan-
cial impact (MPFI) of a new medicine on the UK (UK) National Health Service (NHS)
and the probability of the drug being recommended for use in England and Wales
by the National Institute for Health and Clinical Excellence (NICE).METHODS:Data
were abstracted from the NICE guidance document and costing template for deci-
sions made about drugs between January 2001 and March 2011. MPFI was calcu-
lated by multiplying the population eligible for treatment with the new drug based
on the UK marketing indication by the upper bound estimate for the annual cost of
treatment. Descriptive, logistic, and recursive partitioning decision analyses were
used to estimate the relationship between the MPFI of a new medicine and the
probability of recommendation for use with or without restrictions. Multivariable
analyses controlled for other clinical and economic variables that have been shown
to be correlated with the probability of recommendation for use, including the cost
per quality-adjusted life-year (QALY) gained.RESULTS: In all analyses, MPFI was an
important predictor of the recommendation for use, in addition to cost per QALY.
In the univariate analysis, the mean MPFI was £140 million for medicines not
recommended and £92 million and £31 million for those recommended with and
without restrictions, respectively. In the logistic analysis, the coefficient on the
MPFI variable was statistically significant. In the recursive partitioning decision
analysis, the second split of the data for classifying recommendations, after cost
per QALY, was for submissions with an MPFI above or below £130 million.
CONCLUSIONS: In England and Wales, besides cost-effectiveness ratio, MPFI on
the NHS may be an important determinant of whether a new drug is recommended
for use with or without restrictions.
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OBJECTIVES: To develop a method that enables estimation of a single value func-
tion using data from discrete choice (DC) and time trade off (TTO) questionnaires
and to analyse the informative value of an additional TTO question versus that of
an additional DC. METHODS: Separate DCE and TTO studies are designed with
varying numbers of health states (EQ-5D) to be valued. The DC states do not hold a
time dimension. An optimal Federov design is chosen for the TTO states, a Bayes-
ian approach is followed for the DC states. The base line is blocked design of 20
blocks with 10 DCE’s and 20 blocks of 5 TTO’s. Responses are simulated to both
study-types using prior expectations about answering behaviour, including 10% of
individuals who do not trade time when judging TTO states. Models are estimates
separately as well as simultaneously. For the latter all information is combined
using a likelihood approach assuming a generalised linear model underlying the
answers to the DC comparisons as well as to the TTO questions. The informative
value of adding an additional DC or TTO is measured by the average precision
surrounding the model parameters. RESULTS: While the TTO data offer sufficient
data to identify a value function, the DC data need normalizing constants. Com-
bining both approaches by estimating a single likelihood function takes care of this
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